Redox Signaling and Cancer Drug Action
Redox Signaling and Cancer Drug Action
批准号:
8637738
负责人:
GARTH POWIS
金额:
$32.65万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-01 至 2015-01-31
关键词:
Angiogenic FactorAntineoplastic AgentsApoptoticCancer Cell GrowthCell DeathCell SurvivalCell physiologyCellsClinical TrialsColorectal CancerCorrelative StudyCysteineDevelopmentDrosophila genusDrug TargetingDrug effect disorderEndoplasmic ReticulumFamily memberFibroblast Growth Factor 2GenesGeneticGrantGrowthGrowth FactorHeat shock proteinsHumanIn VitroLysophospholipidsMalignant NeoplasmsMediatingModificationMolecular TargetOxidation-ReductionPathway interactionsPatientsPhase II Clinical TrialsPhosphorylationPolyaminesPost-Translational Protein ProcessingProteinsRegulationResearch DesignRoleSignal PathwaySignal TransductionSignaling ProteinSmall Interfering RNAStressSulfhydryl CompoundsTestingThioredoxinTranslationsVascular Endothelial Growth FactorsWorkbasecancer celldrug developmentdrug discoveryexperienceflyin vivoinhibitor/antagonistlysophosphatidic acidnoveloxidationpleurotinresponsestress proteinthioredoxin reductasetumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Thioredoxin family members involved in cellular protein signaling networks provide an important mechanism
regulating many aspects of cell function including proliferation and cell survival. Redox signaling involves a
protein post translational modification second in importance only to protein phosphorylation. Unlike protein
phosphorylation little is known of redox signaling networks in the cell or how they are altered in cancer. The
increased expression of one redox signaling protein in particular thioredoxin-1 (Trx-1) has been associated
with aggressive tumor growth, decreased apoptotic cell death and decreased patient survival. The hypothesis
upon which our studies are based is that redox signaling through thioredoxin family members is an important
signaling mechanism that is deranged in cancer and that understanding redox signaling networks in the cancer
cell will allow the identification of novel molecular targets for cancer drug discovery and development, and new
strategies to treat cancer. We have used Drosophila genetics together with functional genetic siRNA studies in
human cancer cells to identify new redox signaling pathways which we will investigate in human cancer cells.
We will also investigate the redox regulation of the unfolded protein response (UPR) which is important for
maintaining the synthesis of cell survival proteins during stress, including many angiogenic factors important in
cancer. We will conduct in vivo antitumor and mechanistic studies of an inhibitor of Trx-1 in colorectal cancer
and of a new antitumor inhibitor of thioredoxin reductase we have developed. The overall objective of our
studies is to use redox signaling pathways in cancer to identify new molecular targets for cancer drug
discovery and development, and to provide new strategies to treat cancer. The work builds upon our past
studies of Trx-1 as a cancer drug target which has led to the development of one cancer drug in clinical trial,
and seeks to identify new pathways of redox signaling by thioredoxin family members for the identification of
molecular targets for cancer drug discovery.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2005-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[B. Jordan;M. Runquist;N. Raghunand;R. Gillies;W. Tate;G. Powis;A. Baker]
通讯作者:
B. Jordan;M. Runquist;N. Raghunand;R. Gillies;W. Tate;G. Powis;A. Baker
DOI:
10.1007/s00280-010-1500-0
发表时间:
2011-08
期刊:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
影响因子:
3
作者:
[Kim, Yon Hui, Coon, Amy, Baker, Amanda F., Powis, Garth]
通讯作者:
Powis, Garth
DOI:
10.1007/s12274-009-9026-7
发表时间:
2009-04-17
期刊:
NANO RESEARCH
影响因子:
9.9
作者:
[Bartholomeusz, Geoffrey, Cherukuri, Paul, Kingston, John, Cognet, Laurent, Lemos, Robert, Jr., Leeuw, Tonya K., Gumbiner-Russo, Laura, Weisman, R. Bruce, Powis, Garth]
通讯作者:
Powis, Garth
DOI:
10.1016/j.freeradbiomed.2008.12.012
发表时间:
2009-03-15
期刊:
FREE RADICAL BIOLOGY AND MEDICINE
影响因子:
7.4
作者:
[James, Brian P., Staatz, William D., Wilkinson, Sarah T., Meuillet, Emmanuelle, Powis, Garth]
通讯作者:
Powis, Garth
Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse.
角化细胞定向硫氧还蛋白-1 转基因小鼠皮肤癌发生增加。
DOI:
10.1093/carcin/bgh195
发表时间:
2004
期刊:
Carcinogenesis.
影响因子:
--
作者:
[Mustacich,Debbie, Wagner,Amary, Williams,Ryan, Bair,Warner, Barbercheck,Loretta, Stratton,StevenP, Bhattacharyya,AchyutK, Powis,Garth]
通讯作者:
Powis,Garth
Targeting ERK5 for Colorectal Cancer Therapy
-
批准号:10021322
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2020
-
负责人:GARTH POWIS
-
依托单位:
Targeting ERK5 for Colorectal Cancer Therapy
-
批准号:10357462
-
项目类别:
-
资助金额:$16.95万
-
财政年份:2020
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
-
批准号:10357451
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2018
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
-
批准号:10494262
-
项目类别:
-
资助金额:$49.81万
-
财政年份:2018
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:8964895
-
项目类别:
-
资助金额:$62.41万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:9301505
-
项目类别:
-
资助金额:$62.41万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
-
批准号:9485728
-
项目类别:
-
资助金额:$8.28万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
PLEKHA7 and beta-catenin interact to regulate mutant KRas
-
批准号:9251596
-
项目类别:
-
资助金额:$7.03万
-
财政年份:2015
-
负责人:GARTH POWIS
-
依托单位:
Hypoxia and Anticancer Drug Action
-
批准号:8637740
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8637741
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8637688
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8842459
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8685191
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8842939
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2013
-
负责人:GARTH POWIS
-
依托单位:
Exploiting tumor stroma interactions for cancer therapy
-
批准号:8217439
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:GARTH POWIS
-
依托单位:
Inhibiting oncogenic KRAS for cancer therapy
-
批准号:8292831
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:7629721
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:7837614
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:8061629
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
Chemoprevention by a Targeted Thioredoxin Inhibitor.
-
批准号:7530777
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:GARTH POWIS
-
依托单位:
海外基金